A recent placebo-controlled, double-blind, randomized study indicates that recombinant thrombomodulin, which directly binds to HMGB1 and improves its degradation by thrombin, has a preventive effect against oxaliplatin-induced PN (Kotaka et al., 2020). Here, THBD is linked to poikiloderma with neutropenia.